Cytochrome P450 2D6 (CYP2D6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results

Forensic Science International

Volumn 99, Issue 1, 1999, Pages 25-34

  Druid, Henrik ^a   Holmgren, Per ^a   Carlsson, Björn ^a   Ahlner, Johan ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

CYP2D6; Drug interaction; Forensic medicine; PCR method; Poor metabolizer; Toxicology

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE;

ADULT; AGED; ARTICLE; AUTOPSY; CONTROLLED STUDY; DRUG INTOXICATION; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0032917451     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0379-0738(98)00169-8     Document Type: Article

References (29)

1. Stead A.H., Moffat A.C. A collection of therapeutic, toxic and fatal blood drug concentrations in man. Hum. Toxicol. 3:1983;437-464.
2. Baselt R.C., Cravey R.H. A compendium of therapeutic and toxic concentrations of toxicologically significant drugs in human biofluids. J. Anal. Toxicol. 1:1977;81-103.
3. Schultz M., Schmoldt A. Zusammenstellung therapeutischer und toxischer Plasmakonzentrationsbereiche von Arzneistoffen. Anaesthesist. 43:1994;835-844.
4. Druid H., Holmgren P. A compilation of fatal and control concentrations of drugs in postmortem femoral blood. J. Forensic Sci. 42(1):1997;79-87.
5. Druid H., Holmgren P. Epileptic seizures associated with chronic trimipramine poisoning. Forensic Sci. Int. 49:1991;75-79.
6. Jones G.R. Compilations of therapeutic drug levels. TIAFT Bulletin. 25(4):1994;15-18.
7. Swanson J.R., Jones G.R., Krasselt W., Denmark L.N., Ratti F. Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: A review of the literature and possible mechanisms. J. Forensic Sci. 42(2):1997;335-339.
8. Apple F.S. Postmortem tricyclic antidepressant concentration: Assessing cause of death using parent drug to metabolite ratio. J. Anal. Toxicol. 13:1989;197-198.
9. Nemeroff C.B., DeVane C.L., Pollock B.G. Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry. 153(3):1996;311-320.
10. Mahgoub A., Idle J.R., Dring L.G., Lancaster R., Smith R.L. Polymorphic hydroxylation of debrisoquine in man. Lancet. 2:1977;584-586.
11. Eichelbaum M., Spannbrucker N., Steincke B., Dengler H.J. Defective N-oxidation of spartein in man: a new pharmacogenetic defect. Eur. J. Pharmacol. 16:1979;183-187.
12. Brosen K., Gram L.F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur. J. Clin. Pharmacol. 36:1989;537-547.
13. Brosen K. Recent developments in hepatic drug oxidation: implications from clinical pharmacokinetics. Clin. Pharmacokinet. 18:1990;220-239.
14. Meyer U.A., Amrein R., Balant et al L.P. Antidepressants and drug-metabolizing enzymes - expert group report. Acta Psychiatr. Scand. 93:1996;71-79.
15. Ingelman-Sundberg M., Johansson I., Dahl M.L., Bertilsson L., Yue Y.Q., Sjoqvist F. Genotyping predicts the phenotype for drug metabolism. Läkartidningen. 89(19):1992;1675-1678.
16. Chen S., Chou W.H., Blouin et al R.A. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry. Clin. Pharmacol. Ther. 60:1996;522-534.
17. Druid H., Holmgren P., Löwenhielm P. Computer-assisted systems for forensic medicine and toxicology. J. Forensic Sci. 41(5):1996;830-836.
18. Walsh P.S., Metzeer D.A., Higuchi R. Chelex® 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechniques. 104:1991;506-513.
19. Heim M., Meyer U.A. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet. 336:1990;529-532.
20. Heim M., Meyer U.A. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6. Methods Enzymol. 206:1991;173-183.
21. Steiner E., Bertilsson L., Sawe J., Bertling I., Sjöqvist F. Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin. Pharmacol. Ther. 44:1988;431-435.
22. Bertilsson L., Alm C., de la Carreras C., Edman G., Schalling D., Widén J. Debrisoquine hydroxylation polymorphism and personality. Lancet. i:1989;555.
23. Llerena A., Edman G., Cobaleda J., Benitez J., Schalling D., Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 14:1992;261-264.
24. Dahl M.L., Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics. 3:1993;61-70.
25. Spigset O., Granberg K., Hagg S., Norström A., Dahlqvist R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur. J. Clin. Pharmacol. 52(2):1996;129-133.
26. Carillo J.A., Dahl M.L., Svensson J.O., Alm C., Rodriguez I., Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYPIA2 activity. Clin. Pharmacol. Ther. 60(2):1996;183-190.
27. Busse D., Cosme J., Beaune P., Kroemer H.K., Eichelbaum M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn-Schmidebergs Arch. Pharmacol. 353(1):1995;116-121.
28. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 24:1993;203-220.
29. Guengerich F.P. Mechanism-based inactivation of human liver microsomal cytochrome P450IIIA4 by gestodene. Chem. Res. Toxicol. 3:1990;363-371.